

CLAIMS

1. A method of treating, remedying or preventing psoriasis in a subject comprising administering to the subject a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation.
5
2. The method according to claim 1, wherein the at least one CGRP antagonist compound is selected from the group consisting of 4-sulfinyl benzamide compounds, 3,4-dinitrobenzamide compounds, benzamidazoliny piperadine compounds, anti-CGRP antibodies, CGRP derivatives including the peptide CGRP 8-37, tryptase active polypeptide, and the compound BIBN4096BS, and compound stabilising tryptase, including heparin.
10
3. The method according to claim 1, wherein the CGRP antagonist compound is administered locally, such as topically, dermally, intradermally, or subcutaneously, or via dermal or subcutaneous infusion such as through microdialysis administration.
15
4. The method according to claim 1, wherein the CGRP antagonist compound is administered orally, nasally, rectally, pulmonary, buccally or via subcutaneous, intravenous or intramuscular injection.
20
5. The method according to claim 1, wherein the CGRP antagonist compound is administered topically.
6. The use of a CGRP antagonist compound for the manufacture of a medicament for treating, preventing or remedying psoriasis in a subject.
25
7. The use according to claim 6, wherein the compound is selected from the group comprising 4-sulfinyl benzamide compounds, 3,4-dinitrobenzamide compounds, benzamidazoliny piperadine compounds, anti-CGRP antibodies, CGRP derivatives including CGRP 8-37, tryptase, tryptase stabilizing compounds including heparin, and the compound BIBN4096BS.
30
8. The use according to claim 6, wherein the medicament is administered topically.
9. A pharmaceutical composition for treatment of psoriasis comprising at least one active CGRP antagonist substance and at least one pharmaceutically acceptable excipient.
35

10. The pharmaceutical composition according to claim 9, which composition is for topical, dermal, intradermal, subcutaneous, iontophoretic administration or for administration via infusion such as by microdialysis.

5 11. The pharmaceutical composition according to claim 10, which composition is for topical administration.

12. A method of identifying a candidate compound for use in a medicament for treating psoriasis comprising the steps of:

- 10 (i) obtaining a compound suspected of binding to a CGRP receptor;
- (ii) adding the compound at varying concentrations in the range of about 0.1 μ M to 1 mM to samples comprising CGRP receptors and incubating for a suitable time;
- (iii) adding labeled CGRP peptide to the incubated samples;
- (iv) determining the binding of the labeled CGRP peptide to the CGRP receptor in the
- 15 samples with varying concentration of the compound; and
- (v) determining the binding affinity of the compound to the CGRP receptor;

whereby a compound that is determined to bind the CGRP receptor is identified as a candidate compound for use in a medicament for treating psoriasis.

20 13. The method of claim 11 wherein said samples comprise live cells having surface bound CGRP receptors.

14. The method of claim 11 wherein said samples comprise cell membrane preparations.